mGluR2 Positive Allosteric Modulators for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological tools targeting the mGluR2 receptor, such as structural analogues of glutamate, have poor pharmacokinetic profiles and poor brain penetration, leading to tolerance issues and side effects in treating psychiatric disorders like anxiety and schizophrenia.
Innovation Solution
Development of novel compounds of Formula I, which act as positive allosteric modulators (PAMs) for the mGluR2 receptor, designed to selectively bind to an allosteric site, thereby retaining spatial and temporal activity of glutamate transmission and potentially avoiding tolerance and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If structural analogues of glutamate are used as orthosteric agonists for mGluR2, then receptor activation and therapeutic effect are achieved, but pharmacokinetic profiles deteriorate and brain penetration is poor
Solution Approach 1:
The patent introduces positive allosteric modulators as intermediary substances that bind to an allosteric site on the mGluR2 receptor rather than competing directly with glutamate at the orthosteric site. This mediator approach allows for improved pharmacokinetic properties while maintaining therapeutic efficacy, as the PAMs can be designed with favorable ADME characteristics and do not share the same binding site constraints as orthosteric agonists.
Solution Approach 2:
The patent changes the binding mode parameter from orthosteric to allosteric, fundamentally altering how the ligand interacts with the receptor. This parameter change enables the development of compounds with improved brain penetration and pharmacokinetic profiles, as allosteric modulators can be designed with different structural and physicochemical properties that favor CNS penetration and metabolic stability.
2Reliability
If orthosteric agonists are administered repeatedly, then therapeutic effect is maintained, but tolerance develops and side effects increase
Solution Approach 1:
By using positive allosteric modulators as intermediaries that enhance glutamate signaling rather than providing continuous direct activation, the patent reduces the development of tolerance. The PAMs work by modulating the receptor's response to endogenous glutamate, creating a more physiological signaling pattern that is less prone to adaptive changes and tolerance compared to continuous orthosteric agonist administration.
Solution Approach 2:
The patent implements periodic action through the mechanism of positive allosteric modulation, where the modulator enhances the effect of naturally occurring glutamate releases rather than providing continuous stimulation. This periodic enhancement of glutamate signaling mimics natural neurotransmission patterns, reducing the likelihood of tolerance development and adverse effects associated with continuous agonist exposure.
3Reliability
If continuous stimulation of mGluR2 is provided by orthosteric agonists, then receptor activity is maintained, but spatial and temporal activity of glutamate transmission is altered
Solution Approach 1:
The patent uses positive allosteric modulators as intermediaries that preserve the natural spatial and temporal patterns of glutamate transmission. Rather than continuously stimulating the receptor, the PAMs enhance the impact of endogenous glutamate releases at their natural locations and times, thereby maintaining the physiological composition and dynamics of neurotransmission while achieving therapeutic receptor activation.
Solution Approach 2:
The patent enables the system to serve itself by having the positive allosteric modulators enhance the natural glutamate signaling pathway rather than replacing it. The endogenous glutamate transmission system remains intact and self-regulating, with the PAMs providing a modulatory boost that preserves the natural temporal and spatial characteristics of neurotransmission while achieving therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate therapeutic efficacy in treating anxiety, schizophrenia, epilepsy, addiction, Parkinson's disease, pain, sleep disorders, and Huntington's disease by modulating the mGluR2 receptor, offering improved safety profiles and bioavailability compared to traditional orthosteric agonists.
Implementation Method 1
positive allosteric modulators (PAMs) only activate the receptor when glutamate or another orthosteric agonist is present. Therefore, PAMs are thought to retain spatial and temporal activity of glutamate transmission in the brain
Data Source
AI summary
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. Formula (I):